Cellectis S.A Shares Outstanding 2015-2021 | CLLS

Cellectis S.A shares outstanding from 2015 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Cellectis S.A Annual Shares Outstanding
(Millions of Shares)
2020 43
2019 42
2018 41
2017 36
2016 35
2015 35
2014 26
Cellectis S.A Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 45
2021-03-31 43
2020-12-31 43
2020-09-30 42
2020-06-30 42
2020-03-31 42
2019-12-31 42
2019-09-30 42
2019-06-30 42
2019-03-31 42
2018-12-31 41
2018-09-30 42
2018-06-30 42
2018-03-31 36
2017-12-31 36
2017-09-30 36
2017-06-30 36
2017-03-31 35
2016-12-31 35
2016-09-30 36
2016-06-30 35
2016-03-31 36
2015-12-31 36
2015-09-30 36
2015-06-30 35
2015-03-31 32
2014-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.614B $0.082B
Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis SA is based in Paris, France.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29